Literature DB >> 2192706

The effect of amylin and calcitonin gene-related peptide on insulin-stimulated glucose transport in the diaphragm.

J S Hothersall1, R P Muirhead, S Wimalawansa.   

Abstract

The two peptides calcitonin gene related peptide (CGRP) and amylin at 1 uM levels in an isolated rat diaphragm preparation inhibited insulin stimulated 2-deoxy[3H]glucose transport by 30 and 60 percent, respectively; this was the case at maximal (1 uM) and sub-maximal (0.5 mU) insulin concentrations. No effect was measured on the basal level of 2-deoxy[3H]glucose transport.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2192706     DOI： 10.1016/0006-291x(90)90352-n

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Islet amyloid polypeptide--a novel controversy in diabetes research.

Authors:  P Westermark; K H Johnson; T D O'Brien; C Betsholtz
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

Review 2.  Mechanisms of amyloid beta protein-induced modification in ion transport systems: implications for neurodegenerative diseases.

Authors:  J I Kourie
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

3.  Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vitro incubated human muscle strips.

Authors:  J R Zierath; D Galuska; A Engström; K H Johnson; C Betsholtz; P Westermark; H Wallberg-Henriksson
Journal:  Diabetologia       Date:  1992-01       Impact factor: 10.122

4.  Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes.

Authors:  D R Poyner; D P Andrew; D Brown; C Bose; M R Hanley
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

Review 5.  The metabolic face of migraine - from pathophysiology to treatment.

Authors:  Elena C Gross; Marco Lisicki; Dirk Fischer; Peter S Sándor; Jean Schoenen
Journal:  Nat Rev Neurol       Date:  2019-10-04       Impact factor: 42.937
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.